Till sidinnehåll

Referenser

Ahlen J, Karlsson F, Wejde J, Nilsson IL, Larsson C, Branstrom R. Wide Surgical Margin Improves the Outcome for Patients with Gastrointestinal Stromal Tumors (GISTs). World journal of surgery. 2018;42(8):2512-21.

Almond LM, Gronchi A, Strauss D, Jafri M, Ford S, Desai A. Neoadjuvant and adjuvant strategies in retroperitoneal sarcoma. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2018;44(5):571-9.

Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN guidelines on nutrition in cancer patients. Clinical nutrition (Edinburgh, Scotland). 2017;36(1):11-48.

Baldini EH, Abrams RA, Bosch W, Roberge D, Haas RLM, Catton CN, et al. Retroperitoneal Sarcoma Target Volume and Organ at Risk Contour Delineation Agreement Among NRG Sarcoma Radiation Oncologists. International journal of radiation oncology, biology, physics. 2015;92(5):1053-9.

Baldini EH, Bosch W, Kane JM, 3rd, Abrams RA, Salerno KE, Deville C, et al. Retroperitoneal sarcoma (RPS) high risk gross tumor volume boost (HR GTV boost) contour delineation agreement among NRG sarcoma radiation and surgical oncologists. Annals of surgical oncology. 2015;22(9):2846-52.

Baldini EH, Wang D, Haas RL, Catton CN, Indelicato DJ, Kirsch DG, et al. Treatment Guidelines for Preoperative Radiation Therapy for Retroperitoneal Sarcoma: Preliminary Consensus of an International Expert Panel. International journal of radiation oncology, biology, physics. 2015;92(3):602-12.

Ballinger ML, Goode DL, Ray-Coquard I, James PA, Mitchell G, Niedermayr E, et al. Monogenic and polygenic determinants of sarcoma risk: an international genetic study. Lancet Oncol. 2016;17(9):1261-71.

Barncancerfonden. Vårdplaneringsgruppen för Solida Tumörer hos Barn (VSTB) 2017 [Cited 2020-10-08]. Available from: https://www.barncancerfonden.se/for-forskare/forskningsinfrastruktur/vstb---vardplaneringsgruppen-for-solida-tumorer-hos-barn/.

Bauer HC, Trovik CS, Alvegard TA, Berlin O, Erlanson M, Gustafson P, et al. Monitoring referral and treatment in soft tissue sarcoma: study based on 1,851 patients from the Scandinavian Sarcoma Group Register. Acta Orthop Scand. 2001;72(2):150-9.

Beckmann MW, Juhasz-Boss I, Denschlag D, Gass P, Dimpfl T, Harter P, et al. Surgical Methods for the Treatment of Uterine Fibroids - Risk of Uterine Sarcoma and Problems of Morcellation: Position Paper of the DGGG. Geburtshilfe und Frauenheilkunde. 2015;75(2):148-64.

Benson C, Miah AB. Uterine sarcoma - current perspectives. International journal of women's health. 2017;9:597-606.

Bevilacqua RG, Rogatko A, Hajdu SI, Brennan MF. Prognostic factors in primary retroperitoneal soft-tissue sarcomas. Archives of surgery (Chicago, Ill : 1960). 1991;126(3):328-34.

Blackmon SH, Shah N, Roth JA, Correa AM, Vaporciyan AA, Rice DC, et al. Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival. Ann Thorac Surg. 2009;88(3):877-84; discussion 84-5.

Bonvalot S, Gronchi A, Le Péchoux C, Swallow CJ, Strauss D, Meeus P, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(10):1366-77.

Borgfeldt C, Andolf E. Transvaginal ultrasonographic findings in the uterus and the endometrium: low prevalence of leiomyoma in a random sample of women age 25-40 years. Acta obstetricia et gynecologica Scandinavica. 2000;79(3):202-7.

Bradley KA, Rubinsky AD, Sun H, Bryson CL, Bishop MJ, Blough DK, et al. Alcohol screening and risk of postoperative complications in male VA patients undergoing major non-cardiac surgery. J Gen Intern Med. 2011;26(2):162-9.

Brennan B, Kirton L, Marec-Berard P, Martin -Broto J, Gelderblom H, Gaspar N, et al. Comparison of two chemotherapy regimens in Ewing sarcoma (ES): Overall and subgroup results of the Euro Ewing 2012 randomized trial (EE2012). Journal of Clinical Oncology. 2020;38(15_suppl):11500-.

Bucher P, Egger JF, Gervaz P, Ris F, Weintraub D, Villiger P, et al. An audit of surgical management of gastrointestinal stromal tumours (GIST). European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2006;32(3):310-4.

Bumming P, Andersson J, Meis-Kindblom JM, Klingenstierna H, Engstrom K, Stierner U, et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer. 2003;89(3):460-4.

Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Supplement_4):iv51-iv67.

Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, et al. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv79-iv95.

Cederholm T, Bosaeus I, Barazzoni R, Bauer J, Van Gossum A, Klek S, et al. Diagnostic criteria for malnutrition - An ESPEN Consensus Statement. Clinical nutrition (Edinburgh, Scotland). 2015;34(3):335-40.

Choudhury A, Zhao H, Jalali F, Al Rashid S, Ran J, Supiot S, et al. Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Molecular cancer therapeutics. 2009;8(1):203-13.

Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, et al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(15):1563-70.

Demetri GD, Antonescu CR, Bjerkehagen B, Bovée J, Boye K, Chacón M, et al. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Ann Oncol. 2020;31(11):1506-17.

Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295-302.

Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329-38.

Derbel O, Heudel PE, Cropet C, Meeus P, Vaz G, Biron P, et al. Survival impact of centralization and clinical guidelines for soft tissue sarcoma (A prospective and exhaustive population-based cohort). PloS one. 2017;12(2):e0158406.

Dumitra S, Gronchi A. The Diagnosis and Management of Retroperitoneal Sarcoma. Oncology (Williston Park, NY). 2018;32(9):464-9.

Egholm JW, Pedersen B, Moller AM, Adami J, Juhl CB, Tonnesen H. Perioperative alcohol cessation intervention for postoperative complications. The Cochrane database of systematic reviews. 2018;11:Cd008343.

Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clinical orthopaedics and related research. 1980(153):106-20.

Eriksson M, Reichardt P, Sundby Hall K, Schutte J, Cameron S, Hohenberger P, et al. Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence? European journal of cancer (Oxford, England : 1990). 2016;59:128-33.

Esmo European Sarcoma Network Working Group. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii100-9.

European Partnership Action Against Cancer consensus g, Borras JM, Albreht T, Audisio R, Briers E, Casali P, et al. Policy statement on multidisciplinary cancer care. European journal of cancer (Oxford, England : 1990). 2014;50(3):475-80.

European Sarcoma Network Working Group (ESMO). Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii102-12.

Farag S, Geus-Oei LF, van der Graaf WT, van Coevorden F, Grunhagen D, Reyners AKL, et al. Early Evaluation of Response Using (18)F-FDG PET Influences Management in Gastrointestinal Stromal Tumor Patients Treated with Neoadjuvant Imatinib. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2018;59(2):194-6.

Frassanito L, Vergari A, Nestorini R, Cerulli G, Placella G, Pace V, et al. Enhanced recovery after surgery (ERAS) in hip and knee replacement surgery: description of a multidisciplinary program to improve management of the patients undergoing major orthopedic surgery. Musculoskeletal surgery. 2019.

Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol. 2017;18(8):1022-39.

Gavamukulya Y, El-Shemy HA, Meroka AM, Madivoli ES, Maina EN, Wamunyokoli F, et al. Advances in green nanobiotechnology: Data for synthesis and characterization of silver nanoparticles from ethanolic extracts of fruits and leaves of Annona muricata. Data in brief. 2019;25:104194.

Grimer R, Judson I, Peake D, Seddon B. Guidelines for the management of soft tissue sarcomas. Sarcoma. 2010;2010:506182.

Grünwald V, Karch A, Schuler M, Schöffski P, Kopp HG, Bauer S, et al. Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020;38(30):3555-64.

Gustafson P. Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. Acta orthopaedica Scandinavica Supplementum. 1994;259:1-31.

Gutierrez JC, Perez EA, Moffat FL, Livingstone AS, Franceschi D, Koniaris LG. Should soft tissue sarcomas be treated at high-volume centers? An analysis of 4205 patients. Annals of surgery. 2007;245(6):952-8.

Haas RL, Baldini EH, Chung PW, van Coevorden F, DeLaney TF. Radiation therapy in retroperitoneal sarcoma management. Journal of surgical oncology. 2018;117(1):93-8.

Hui EP, Ma BB, King AD, Mo F, Chan SL, Kam MK, et al. Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. Ann Oncol. 2011;22(6):1280-7.

Irtan S, Van Tinteren H, Graf N, van den Heuvel-Eibrink MM, Heij H, Bergeron C, et al. Evaluation of needle biopsy as a potential risk factor for local recurrence of Wilms tumour in the SIOP WT 2001 trial. European journal of cancer (Oxford, England : 1990). 2019;116:13-20.

Iwakawa M, Noda S, Yamada S, Yamamoto N, Miyazawa Y, Yamazaki H, et al. Analysis of non-genetic risk factors for adverse skin reactions to radiotherapy among 284 breast cancer patients. Breast cancer (Tokyo, Japan). 2006;13(3):300.

Jagsi R, Griffith KA, Koelling T, Roberts R, Pierce LJ. Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer. 2007;109(4):650-7.

Jian BJ, Bloch OG, Yang I, Han SJ, Aranda D, Tihan T, et al. Adjuvant radiation therapy and chondroid chordoma subtype are associated with a lower tumor recurrence rate of cranial chordoma. Journal of neuro-oncology. 2010;98(1):101-8.

Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, et al. Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016;34(3):244-50.

Joensuu H, Wardelmann E, Sihto H, Eriksson M, Sundby Hall K, Reichardt A, et al. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial. JAMA oncology. 2017;3(5):602-9.

Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Human pathology. 2008;39(10):1411-9.

Johnson GD, Smith G, Dramis A, Grimer RJ. Delays in referral of soft tissue sarcomas. Sarcoma. 2008;2008:378574.

Judson I, Verweij J, Gelderblom H, Hartmann JT, Schoffski P, Blay JY, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415-23.

Kadam PD, Chuan HH. Erratum to: Rectocutaneous fistula with transmigration of the suture: a rare delayed complication of vault fixation with the sacrospinous ligament. International urogynecology journal. 2016;27(3):505.

Kang YK, Ryu MH, Yoo C, Ryoo BY, Kim HJ, Lee JJ, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1175-82.

Karakousis CP, Velez AF, Gerstenbluth R, Driscoll DL. Resectability and survival in retroperitoneal sarcomas. Annals of surgical oncology. 1996;3(2):150-8.

Kasper B, Baumgarten C, Bonvalot S, Haas R, Haller F, Hohenberger P, et al. Management of sporadic desmoid-type fibromatosis: A European consensus approach based on patients’ and professionals’ expertise – A Sarcoma Patients EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative. European Journal of Cancer. 2015;51(2):127-36.

Kasper B, Baumgarten C, Garcia J, Bonvalot S, Haas R, Haller F, et al. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Annals of Oncology. 2017;28(10):2399-408.

Kaufman EL, Jacobson JS, Hershman DL, Desai M, Neugut AI. Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(3):392-8.

Laughlin-Tommaso SK, Jacoby VL, Myers ER. Disparities in Fibroid Incidence, Prognosis, and Management. Obstetrics and gynecology clinics of North America. 2017;44(1):81-94.

Laurent H, Aubreton S, Galvaing G, Pereira B, Merle P, Richard R, et al. Preoperative respiratory muscle endurance training improves ventilatory capacity and prevents pulmonary postoperative complications after lung surgery: a randomized controlled trial. European journal of physical and rehabilitation medicine. 2019.

Le Cesne A, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol. 2010;11(10):942-9.

Leithner A, Schnack B, Katterschafka T, Wiltschke C, Amann G, Windhager R, et al. Treatment of extra-abdominal desmoid tumors with interferon-alpha with or without tretinoin. Journal of surgical oncology. 2000;73(1):21-5.

Lewis JJ, Leung D, Woodruff JM, Brennan MF. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Annals of surgery. 1998;228(3):355-65.

Liles JS, Tzeng CW, Short JJ, Kulesza P, Heslin MJ. Retroperitoneal and intra-abdominal sarcoma. Current problems in surgery. 2009;46(6):445-503.

Lolli C, Pantaleo MA, Nannini M, Saponara M, Pallotti MC, Scioscio VD, et al. Successful radiotherapy for local control of progressively increasing metastasis of gastrointestinal stromal tumor. Rare tumors. 2011;3(4):e49.

Ludovisi M, Moro F, Pasciuto T, Di Noi S, Giunchi S, Savelli L, et al. Imaging of gynecological disease: clinical and ultrasound characteristics of uterine sarcomas. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2019.

Malekzadeh F, Rose C, Ingvar C, Jernstrom H. [Natural remedies and hormone preparations--potential risk for breast cancer patients. A study surveys the use of agents which possibly counteract with the treatment]. Lakartidningen. 2005;102(44):3226-8, 30-1.

Marcella C, Shi RH, Sarwar S. Clinical Overview of GIST and Its Latest Management by Endoscopic Resection in Upper GI: A Literature Review. Gastroenterology research and practice. 2018;2018:6864256.

Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. The American journal of surgical pathology. 2005;29(1):52-68.

Mir O, Cropet C, Toulmonde M, Cesne AL, Molimard M, Bompas E, et al. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet Oncol. 2016;17(5):632-41.

Mitchell G, Ballinger ML, Wong S, Hewitt C, James P, Young MA, et al. High frequency of germline TP53 mutations in a prospective adult-onset sarcoma cohort. PloS one. 2013;8(7):e69026.

Murakami M, Ichimura T, Kasai M, Matsuda M, Kawamura N, Fukuda T, et al. Examination of the use of needle biopsy to perform laparoscopic surgery safely on uterine smooth muscle tumors. Oncology letters. 2018;15(6):8647-51.

Nannini M, Biasco G, Pallotti MC, Di Battista M, Santini D, Paterini P, et al. Late recurrences of gastrointestinal stromal tumours (GISTs) after 5 years of follow-up. Medical oncology (Northwood, London, England). 2012;29(1):144-50.

Nath B, Li Y, Carroll JE, Szabo G, Tseng JF, Shah SA. Alcohol exposure as a risk factor for adverse outcomes in elective surgery. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2010;14(11):1732-41.

Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Annals of surgery. 1992;215(1):68-77.

Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden. Cancer. 2005;103(4):821-9.

Nussbaum DP, Rushing CN, Lane WO, Cardona DM, Kirsch DG, Peterson BL, et al. Preoperative or postoperative radiotherapy versus surgery alone for retroperitoneal sarcoma: a case-control, propensity score-matched analysis of a nationwide clinical oncology database. Lancet Oncol. 2016;17(7):966-75.

Peterson C. [Natural remedies--self care at your own risk! Danger of unknown adverse effects and interactions with "common" medications]. Lakartidningen. 2005;102(44):3200-1.

Pillay B, Wootten AC, Crowe H, Corcoran N, Tran B, Bowden P, et al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. Cancer Treat Rev. 2016;42:56-72.

Porter GA, Baxter NN, Pisters PW. Retroperitoneal sarcoma: a population-based analysis of epidemiology, surgery, and radiotherapy. Cancer. 2006;106(7):1610-6.

Prochazka M, Granath F, Ekbom A, Shields PG, Hall P. Lung cancer risks in women with previous breast cancer. European journal of cancer (Oxford, England : 1990). 2002;38(11):1520-5.

Rastrelli M, Tropea S, Basso U, Roma A, Maruzzo M, Rossi CR. Soft tissue limb and trunk sarcomas: diagnosis, treatment and follow-up. Anticancer Res. 2014;34(10):5251-62.

Raut CP, Pisters PW. Retroperitoneal sarcomas: Combined-modality treatment approaches. Journal of surgical oncology. 2006;94(1):81-7.

Rothermundt C, Whelan JS, Dileo P, Strauss SJ, Coleman J, Briggs TW, et al. What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients. Br J Cancer. 2014;110(10):2420-6.

Rutkowski P, Jagielska B, Andrzejuk J, Bylina E, Lugowska I, Switaj T, et al. The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST). Contemporary oncology (Poznan, Poland). 2017;21(4):285-9.

Rutkowski P, Nowecki ZI, Michej W, Debiec-Rychter M, Wozniak A, Limon J, et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Annals of surgical oncology. 2007;14(7):2018-27.

Rydholm A. Management of patients with soft-tissue tumors. Strategy developed at a regional oncology center. Acta orthopaedica Scandinavica Supplementum. 1983;203:13-77.

Saeter G, Hall KS, Bruland OS, Solheim OP, Hoie J, Folleras G, et al. [Bone and soft tissue sarcomas treated at the Norwegian Radium Hospital 1980-99]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. 2002;122(21):2089-94.

Sampo M, Tarkkanen M, Huuhtanen R, Tukiainen E, Bohling T, Blomqvist C. Impact of the smallest surgical margin on local control in soft tissue sarcoma. The British journal of surgery. 2008;95(2):237-43.

Scandinavian Sarcoma Group Trials (SSG). Treatment Protocols and recommendations - Sarcoma 2017 [Cited 2020-10-08]. Available from: http://www.ssg-org.net/treatment-protocols-and-recommendations/ongoing.

Schoffski P, Reichardt P, Blay JY, Dumez H, Morgan JA, Ray-Coquard I, et al. A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann Oncol. 2010;21(10):1990-8.

Sharp L, Johansson H, Hatschek T, Bergenmar M. Smoking as an independent risk factor for severe skin reactions due to adjuvant radiotherapy for breast cancer. Breast. 2013;22(5):634-8.

Stacchiotti S, Negri T, Libertini M, Palassini E, Marrari A, De Troia B, et al. Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol. 2012;23(12):3171-9.

Stacchiotti S, Tamborini E, Marrari A, Brich S, Rota SA, Orsenigo M, et al. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res. 2009;15(3):1096-104.

Storm FK, Mahvi DM. Diagnosis and management of retroperitoneal soft-tissue sarcoma. Annals of surgery. 1991;214(1):2-10.

Styring E, Billing V, Hartman L, Nilbert M, Seinen JM, Veurink N, et al. Simple guidelines for efficient referral of soft-tissue sarcomas: a population-based evaluation of adherence to guidelines and referral patterns. The Journal of bone and joint surgery American volume. 2012;94(14):1291-6.

Temming P, Arendt M, Viehmann A, Eisele L, Le Guin CH, Schundeln MM, et al. Incidence of second cancers after radiotherapy and systemic chemotherapy in heritable retinoblastoma survivors: A report from the German reference center. Pediatr Blood Cancer. 2017;64(1):71-80.

The Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(7):1247-53.

Thenappan A, Halaweish I, Mody RJ, Smith EA, Geiger JD, Ehrlich PF, et al. Review at a multidisciplinary tumor board impacts critical management decisions of pediatric patients with cancer. Pediatr Blood Cancer. 2017;64(2):254-8.

Tonnesen H, Nielsen PR, Lauritzen JB, Moller AM. Smoking and alcohol intervention before surgery: evidence for best practice. British journal of anaesthesia. 2009;102(3):297-306.

Topal B, Smelt HJM, Van Helden EV, Celik A, Verseveld M, Smeenk F, et al. Utility of preoperative exercise therapy in reducing postoperative morbidity after surgery; a clinical overview of current evidence. Expert review of cardiovascular therapy. 2019;17(6):395-412.

Toulmonde M, Bonvalot S, Meeus P, Stoeckle E, Riou O, Isambert N, et al. Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. Ann Oncol. 2014;25(3):735-42.

Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, et al. Pazopanib or methotrexate–vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. The Lancet Oncology. 2019;20(9):1263-72.

Toulmonde M, Ray-Coquard IL, Pulido M, Andre T, Isambert N, Chevreau C, et al. DESMOPAZ pazopanib (PZ) versus IV methotrexate/vinblastine (MV) in adult patients with progressive desmoid tumors (DT) a randomized phase II study from the French Sarcoma Group. 2018;36(15_suppl):11501-.

Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. The American journal of gastroenterology. 2005;100(1):162-8.

Trans-Atlantic RPS Working Group. Management of primary retroperitoneal sarcoma (RPS) in the adult: a consensus approach from the Trans-Atlantic RPS Working Group. Annals of surgical oncology. 2015;22(1):256-63.

Trans-Atlantic RPS Working Group. Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group. Annals of surgical oncology. 2016;23(11):3531-40.

Trovik CS, Bauer HC, Alvegard TA, Anderson H, Blomqvist C, Berlin O, et al. Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register. European journal of cancer (Oxford, England : 1990). 2000;36(6):710-6.

Valentin T, Fournier C, Penel N, Bompas E, Chaigneau L, Isambert N, et al. Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO). Invest New Drugs. 2013;31(6):1626-7.

van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879-86.

Vermaete N, Wolter P, Verhoef G, Gosselink R. Physical activity, physical fitness and the effect of exercise training interventions in lymphoma patients: a systematic review. Annals of hematology. 2013;92(8):1007-21.

Wada N, Takahashi T, Kurokawa Y, Nakajima K, Miyazaki Y, Makino T, et al. [The Characteristics of Patients with GIST Who Experienced Late Recurrence after Resection]. Gan to kagaku ryoho Cancer & chemotherapy. 2016;43(12):2118-20.

Wagner AJ, Malinowska-Kolodziej I, Morgan JA, Qin W, Fletcher CD, Vena N, et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(5):835-40.

Wang YN, Zhu WQ, Shen ZZ, Li S, Liu SY. Treatment of locally recurrent soft tissue sarcomas of the retroperitoneum: report of 30 cases. Journal of surgical oncology. 1994;56(4):213-6.

Weimann A, Braga M, Carli F, Higashiguchi T, Hubner M, Klek S, et al. ESPEN guideline: Clinical nutrition in surgery. Clinical nutrition (Edinburgh, Scotland). 2017;36(3):623-50.

Wells M, Macmillan M, Raab G, MacBride S, Bell N, MacKinnon K, et al. Does aqueous or sucralfate cream affect the severity of erythematous radiation skin reactions? A randomised controlled trial. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2004;73(2):153-62.

Whelan J, Le Deley MC, Dirksen U, Le Teuff G, Brennan B, Gaspar N, et al. High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018:Jco2018782516.

World Health O, International Agency for Research on C, Kurman RJ. WHO Classification of Tumours of Female Reproductive Organs [Elektronisk resurs]: International Agency for Research on Cancer; 2014.

Wu L, Zhang Z, Yao H, Liu K, Wen Y, Xiong L. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials. Drug design, development and therapy. 2014;8:2061-7.

Zerhouni S, Van Coevorden F, Swallow CJ. The role and outcomes of palliative surgery for retroperitoneal sarcoma. Journal of surgical oncology. 2018;117(1):105-10.

Se även Bilaga 2 Gynekologiska sarkom.